Ryan Larson, Ph.D., is VP, Head of Immunology at Umoja Biopharma, where he is responsible for advancing off-the-shelf in vivo lentiviral vector and ex vivo cell-based CAR T cell therapies to the clinic. Prior to Umoja, Ryan was Head of Cell Therapy Analytical Development and Product Sciences at Juno Therapeutics, Celgene, and Bristol Myers-Squibb. Ryan spent time at Thermo Fisher Scientific developing analytical technologies and reagents to enable cell and gene therapy research and development. Ryan earned his PhD in immunology from the University of Washington.
.svg)
